Conformationally linked interaction in the cytochrome bc1 complex between inhibitors of the Qo site and the Rieske iron–sulfur protein  by Berry, Edward A. & Huang, Li-Shar
Biochimica et Biophysica Acta 1807 (2011) 1349–1363
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbab ioConformationally linked interaction in the cytochrome bc1 complex between
inhibitors of the Qo site and the Rieske iron–sulfur protein☆
Edward A. Berry ⁎, Li-Shar Huang
Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA☆ This article is part of a Special Issue entitled: Alloste
proteins.
⁎ Corresponding author at: SUNY Upstate Medical Un
Addition, 750 E. Adams Street, Syracuse, NY 13210, U
fax: +1 315 410 5437.
E-mail address: berrye@upstate.edu (E.A. Berry).
0005-2728/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbabio.2011.04.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 9 February 2011
Received in revised form 1 April 2011
Accepted 1 April 2011







FenamidoneThe modiﬁed Q cycle mechanism accounts for the proton and charge translocation stoichiometry of the bc1
complex, and is now widely accepted. However the mechanism by which the requisite bifurcation of electron
ﬂowat theQo site reaction is enforced is not clear. One of several proposals involves conformational gating of the
docking of the Rieske ISP at the Qo site, controlled by the stage of the reaction cycle. Effects of different Qo-site
inhibitors on the position of the ISP seen in crystals may reﬂect the same conformational mechanism, in which
case understanding how different inhibitors control the position of the ISP may be a key to understanding the
enforcement of bifurcation at the Qo site (Table 1). Here we examine the available structures of cytochrome bc1
with different Qo-site inhibitors and different ISP positions to look for clues to this mechanism. The effect of ISP
removal on binding afﬁnity of the inhibitors stigmatellin and famoxadone suggest a “mutual stabilization” of
inhibitor binding and ISP docking, however this thermodynamic observation sheds little light on themechanism.
The cd1 helix of cytochrome bmoves in such away as to accommodate dockingwhen inhibitors favoring docking
are bound, but it is impossible with the current structures to say whether this movement of α-cd1 is a cause or
result of ISP docking. One component of themovement of the linker between E and F helices also correlates with
the type of inhibitor and ISP position, and seems to be related to the H-bonding pattern of Y279 of cytochrome b.
AnH-bond fromY279 to the ISP, and its possiblemodulationbymovementof F275 in thepresenceof famoxadone
and related inhibitors, or its competition with an alternate H-bond to I269 of cytochrome b that may be
destabilized by bound famoxadone, suggest other possible mechanisms. This article is part of a Special Issue
entitled: Allosteric cooperativity in respiratory proteins.ric cooperativity in respiratory
iversity, 4281 Weiskotten Hall




and PCA, Principle C
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The bc1 complex (complex III, ubiquinol: cytochrome c oxidore-
ductase, E.C.1.10.2.2) plays a central role in the mitochondrial
respiratory chain, oxidizing ubiquinol provided by the dehydroge-
nases and reducing cytochrome c for the oxidase. In the process two
protons are taken up on the matrix side and four protons released on
the inter-membrane side of the membrane per quinol oxidized,
contributing to the proton electrochemical gradient. A similar
cytochrome bc1 complex operates in respiratory and photosynthetic
electron transfer chains of many proteobacteria, and the more
distantly related b6f complex has a similar role in photosynthesis in
cyanobacteria and chloroplasts [1,2].
The bc1 complexes all have a diheme cytochrome b, an iron–sulfur
proteinwith aRieske-type Fe2S2 cluster, andcytochrome c1 thatundergoreduction and oxidation during the turnover of the enzyme. The
mitochondrial complexes have an additional 7–8 subunits whose
function is less clear. The bc1 and b6f complexes are universally dimeric
(i.e. homodimer of hetero-n-mers), leading to the possibility of
cooperative and anticooperative interactions between the monomers.
Fig. 1 compares the overall structure of the bovine enzyme, with 11
subunits, to that of the Rb. capsulatus structure with only the three
universal subunits, and the cytochrome b6f complex with different
supernumerary subunits and cytochrome f instead of cytochrome c1.
General defects in the respiratory chain, often due to large deletions
or rearrangement of mtDNA1 or defects in mitochondrial protein
synthesis, lead to “bioenergetic disease”: various myopathies (ragged-
red-ﬁber and Kearne–Sayre's), or neurodegenerative diseases such as
MELAS (mitochondrial encephalopathy with lactic acidosis and stroke-
like episodes). Speciﬁc defects in the bc1 complex itself have been found
in cases of exercise intolerance [4], cardiomyopathy [5,6],mitochondriale: mtDNA, mitochondrial DNA; ISP, iron–sulfur protein; nQNO,
line-N-oxide; nHDBT, alkylhydroxydioxobenzothiazole; PEWY,
rp-Tyr sequence in the ef loop constituting part of the Qo site;
omponent Analysis
Fig. 1. Cytochrome bc and bf complexes of (left to right) mitochondria, bacteria, and chloroplasts. The purple structure is cytochrome b, yellow is the ISP, and green is cytochrome c1.
Red highlights differences between the bacterial and mitochondrial subunits. The dark brown band represents the approximate position of the membrane.
(Reproduced from reference [3]).
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[10].
The bc1 complex is the target for several important agricultural
fungicides [11,12] and for the antimalarial drug atovaquone [13–16].
Together with Complex I, the bc1 complex is the major source of
reactive oxygen species generation in mitochondria [17], and some of
the neurodegenerative symptoms probably relate to increased ROS
production by the defective complex. ROS and resulting oxidative
stress are important in apoptosis, cancer, and aging. The bifurcation
reaction discussed here seems to be the source of ROS in the bc1
complex [18,19].1.1. The Q-cycle can explain proton pumping and oxidant-induced
reduction, but requires enforced “bifurcation” at the Qo site
The bc1 complex seems to be the only complex of the mitochon-
drial respiratory chain which pumps protons in a purely Mitchellian
fashion, i.e. through asymmetric uptake and release of protons by the
redox reactions themselves. In this mechanism, the “modiﬁed Q cycle”
(Fig. 2), ubiquinol is oxidized at the Qo site, with release of both
protons to the external medium. One electron is transferred to
cytochrome c via the Fe2S2 cluster and cytochrome c1, providing the
driving force for the reaction. The other electron passes back across
the membrane via the hemes of cytochrome b (contributing to theFig. 2. Modiﬁed “protonmotive Q cycle” mechanism for H+ translocation by the bc1
complex. Ubiquinone is processed at two active sites called Qo and Q i (for proton input
and output centers) See text for details. The Qo and Q i sites are also referred to as Q P
and QN, for positive and negative side of the membrane.membrane potential) and reduces quinone at the Qi site, with proton
uptake from the matrix side of the membrane. In two turnovers of the
Qo site four protons will be released externally, two electrons will be
transferred to cytochrome c, and two electrons will cross the
membrane and reduce one quinone with uptake of two protons on
the inside, giving a net oxidation of one quinol. Effectively two charges
will have crossed the full dielectric of the membrane, carried by the
two electrons moving from Qo to Qi, and protons moving in the
opposite direction between the Q sites and the adjacent aqueous
phases. This stoichiometry of charge and proton translocation is
consistent with experimental measurements [20]. The Qo and Qi sites,
originally named as proton output and input Q sites, are often referred
to as center N and center P, for their location on the relatively negative
and positive sides of the membrane.
Proton pumping results from the fact that one electron is recycled
to reduce quinone, with proton uptake, on the input side. If both
electrons went to the high potential chain the bc1 complex could only
function as one half of a proton loop [21], releasing the scalar protons
on the output side. The efﬁciency is increased by the fact that only half
the electrons obtained from oxidizing ubiquinol are actually spent—
the other half are recycled to the Q-pool to be used again, resulting in
two protons translocated and two scalar protons released per two
electrons; as observed.
From this it is clear that there must be some mechanism to ensure
what has come to be called the “bifurcation” of electron transport at
the Q o site, and experimentally this enforced bifurcation can be
demonstrated. If the Q pool is kept reduced and the high potential
chain oxidized, there is a large driving force for the overall reaction.
Now if the Q i site is blocked by antimycin so that the recycled
electrons have nowhere to go, the reaction essentially stops, although
nothing is inhibiting the Qo site. There may be a small leak rate of
electrons reaching cytochrome c, corresponding to a few percent of
normal turnover under these conditions, but most of this is oxygen-
dependent so presumablymediated by ROS [18]. Since the return path
to the Q i site consists of the two hemes of cytochrome b, cytochrome b
becomes highly reduced under these conditions, a state known as
“oxidant-induced reduction”. The mechanism for enforcing this “strict
bifurcation of the electron ﬂow at the Qo site” is one of the most
important questions for understanding energy transduction by the bc1
complex today.
The simplest explanation may be that the reaction mechanism is
concerted, with both electrons transferred simultaneously and the
semiquinone so unstable as not to be formed at appreciable rate under
normal circumstances. This is consistent with the fact that semiqui-
none is not observed under pre-steady-state conditions [22] or even
under conditions of oxidant-induced reduction [23]. If the reaction is
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potential chain, since both the ISP cluster and cytochrome b are one-
electron acceptors. However a number of workers have been reluctant
to accept a concerted mechanism. The strongest criticisms seem to be
the lack of expected dependency of the rate of the reaction on the
redox potential of cytochrome bL [24], the fact that semiquinone is
actually generated under special circumstances [25,26], and arguably
the fact that the activation energy for generation of superoxide in the
presence of antimycin is very similar to that of the overall uninhibited
reaction [27]. Perhaps also the underlying principles governing
concerted reactions are less clear, at least to many of the people
working in this ﬁeld including the current authors. If the reaction goes
by a sequential process, then some mechanism must exist to enforce
bifurcation.
1.2. Allostery and cooperativity in the bc1 complex
Evidence for conformational changes and allosteric interactions
has been accumulating for almost as long as Complex III has been
known. In 1967 Rieske et al. [28] described dramatic stabilization of
the bc1 complex by antimycin or HQNO against dissociation induced
by detergent plus high salt concentrations or guanidinium chloride,
and attributed the effect to long-range conformational effects. Other
observations were interpreted in terms of allostery and cooperative
binding [29–32], however one of the effects involved, the sigmoidal
titration of activity with antimycin, has since been explained by the
“Q-pool effect” [33] andmore recently by rapid exchange of antimycin
between sites in a dimer [34] or electron crossover between the low-
potential b hemes of the dimeric complex [35–40]. Surprisingly,When
X-ray structures of the antimycin-bound bc1 complex became
available, they showed no signiﬁcant conformational change: RMSD
between superimposed Cα of 0.33 Å [41] or 0.13 Å and maximum
deviation 0.28 Å [42]. It may be that antimycin does not affect the
static, “ground state” structure of the complex but limits or modulates
its dynamics.
More recently evidence has been obtained for anticooperative
effects between the monomers of the dimer and half-the-sites
reactivity [39,43]; and allosteric communication between the Q i and
Qo sites on opposite sides of the membrane [44,45]. These ideas will
not be discussed further here, however. The topic of this work, as
explained further below, is the possible allosteric gating of the
bifurcated reaction at the Qo site to enforce the Q-cycle mechanism
and support efﬁcient energy transduction.
1.3. Movement of the Rieske iron–sulfur protein
One unexpected result of the X-ray structures was that the extrinsic
domain of the ISP is found in differentpositions in different crystal forms
or in the presence of different Qo-site inhibitors (Table 1) [46].
Hexagonal bipyramid (P6522) andmonoclinic crystals, and orthorhom-
bic crystals of the chicken bc1 complex, have the ISP positionedwith the
cluster near the heme of cytochrome c1, in what is called the “distal” orTable 1
Inhibitor classes and their effects on the state of the iron–sulfur protein in crystals.
Inhibitor classiﬁcation [49] Examples
Q o, Pm MOA-type inhibitors such as myxothiazol,
azoxystrobin, kresoxym-Me, strobilurins
Q o, Pf Stigmatellin, UHDBT homologs, hydroxynapthoquinones
Famoxadone, fenamidone, JG-144
Q i, N Antimycin, funiculosin, HQNO, ilicicolin H,
sambutoxin, diuron“c1” position [46–48]. Tetragonal (I422), beef crystals have the ISP
positioned with the cluster near the Qo site in cytochrome b [46,47].
However co-crystallization or soaking the chicken bc1 crystals with the
Qo-site inhibitor Stigmatellin [46] resulted in the same position seen in
the tetragonal crystals, which is called the proximal or “b” position.
Various inhibitors modulated occupancy of the ISP as judged by the
intensity of the Fe anomalous peak in the tetragonal crystals [48]. This
led to the conclusion that, contrary to the picture in Fig. 2, the ISP is a
mobile carrier shuttling electrons between its reductant and oxidant.
Since themobile extrinsic domain of the ISP is only tetheredby aﬂexible
neck region, it is unlikely that any forces are exerted on it to make it
move. Rather it is more likely diffusing freely between different
positions, with residence time in particular positions depending on
favorable contacts, that is, binding afﬁnity.
1.3.1. Possible signiﬁcance of the ISP movement for strict bifurcation
The movement of the ISP head domain suggests another possible
explanation for the enforced bifurcation at Qo: the cluster can only
accept one electron at a time, so for both electrons to go down the
high potential path the ISP would have to leave, deliver the electron to
cytochrome c1, and return to get the second electron. In comparison to
a solid-state electron transfer chain where the electrons could speed
through one after the other, this presents a kinetic impediment to
both electrons going to the high potential chain. This kinetic
impediment by itself cannot explain the strict (~99%) inhibition by
antimycin, when turnover is essentially stopped giving the ISP ample
time to return and take the second electron. However some allosteric
modulation of the movement of the ISP could provide conformational
gating to completely eliminate that reaction. Among several types of
explanation for the enforced bifurcation, “catalytic switch” mecha-
nisms have been proposed to limit the high potential chain to
accepting only the ﬁrst electron from quinol. One suggestion is that
the different ISP positions seen in the presence of different inhibitors
reﬂect positional gating by those inhibitors, resembling quinone in
different stages of the reaction cycle. Such gating could prevent the
oxidized ISP from returning until the second electron has been
delivered to cytochrome b, ensuring the bifurcation. If this is the case,
understanding how inhibitors affect the ISP position is likely to reveal
the mechanism of strict bifurcation. A recent explanation from Esser
et al. [49] proposes that the occupant of the Qo site controls the
surface conformation of cytochrome b to allow or prevent docking of
the ISP at the Qo site in such a way as to enforce the bifurcation of
electron ﬂow.
1.3.2. Available X-ray structures for investigating the relation between
Qo ligand and ISP position
As of December 2010 there are 39 structures of mitochondrial bc1
complexes in the protein databank, another ﬁve of bacterial bc1, and
seven cyanobacterial/chloroplast b6f complexes. These structures are
tabulated in Table S1 of supplementary materials. The eukaryotic bc1
structures were obtained from three species crystallized in 7 different
crystal forms (Table 2). For understanding the forces controllingResulting position in chicken orthorhombic
bc1 crystals [46,77 and unpublished]
Resulting state in bovine
tetragonal crystals [48–50]
“c1”=“distal” (cluster near heme of cyt. c1) “Released”
“b”=“proximal” (cluster near Q o site in cyt b) “Fixed”
“Famoxadone position” (described in text)
No crystallographically detectable effects for
those inhibitors (antimycin, HQNO) that have
been determined
2 PDB ID codes are given in lower case except the letter L is in upper case, to avoid
ambiguity between the characters for 1, L, and i; and between the digit 0 and letter o.
Thus 1L0L contains the digit zero not the letter o, and 3h1i contains the digit 1 and the
letter i. Residue numbers in cytochrome b are given in the numbering of the chicken
structures, even when referring to other structures.
Table 2
Different crystal forms of the mitochondrial bc1 complex that have provided structures.
Source Space
group




Beef I4122 [47] 1qcr, 2fyu 1 2.3 m
P6522 [46,78] 1be3 1 3.0 c1
P65 [78] 1bgY 2 3.0 (2.5b) I, m
P212121 [42] 1ppj, 2a06 2 2.1 b, b
Chicken P212121 [46] 1bcc, 3h1h, 3L70 2 2.7 m, m
Yeast C2 [79] 1ezv, 1 kb9,
1p84
1 2.3 b
P21 [80,81] 1kyo, 3cx5 2 1.9 b,b
a Position or state of the ISP extrinsic domain. “Mobile” implies the ability to move in
the crystal, although it may be ﬁxed in b or c1 position in particular structures,
especially in the presence of inhibitors. “I” refers to an intermediate position seen in
one monomer of structure 1bgy.
b Resolution in parentheses is unpublished but reported at meetings or otherwise
known.
1352 E.A. Berry, L.-S. Huang / Biochimica et Biophysica Acta 1807 (2011) 1349–1363position of the ISP, the most useful are the tetragonal (I422) crystals of
the bovine enzyme from Yu and Xia [41,48–51] and our orthorhombic
chicken crystals [46,52]. This is because these two crystal forms have
weak or no crystal contacts involving the ISP, allowing the ISP to take on
different positions in otherwise isomorphous crystals. In addition, and
probably related to the above, these two crystal forms can be obtained
with a variety of different inhibitors or no inhibitor at all in the Qo site,
allowing the effects of different inhibitors to be tested/visualized. The
hexagonal (P6522) crystals have a strong contact on the ISP requiring it
to be in the c1 position for crystallization, while the yeast and
orthorhombic (P212121) bovine crystals require the ISP in the b position
and have only been obtained in the presence of stigmatellin or nHDBT,
whichmaintain that position. Thus these crystal forms each represent a
single structure as far as this work is concerned, whereas multiple
different structures for comparison are obtained from the tetragonal
beef and the chicken crystal forms. Comparing these two crystal forms,
the chicken crystals have a dimer in the asymmetric unit, which makes
for a more favorable effective data-to-parameters ratio at a given
resolution. On the other hand the bovine crystals, which have a
monomer in the asymmetric unit, have been obtained at signiﬁcantly
higher resolution. Movement of the ISP in the crystal can be demon-
strated with the chicken crystals, by crystallizing in the absence of
inhibitor (giving the c1 position) followed by soaking with an inhibitor
such as stigmatellin, which results in the b position.
1.3.3. What controls the position of the ISP: H-bonding, or surface
conformational change? Two explanations for the movement of the ISP
The ﬁrst crystal structure of bc1 was from Xia/Deisenhofer/Yu
tetragonal crystals [47]. These crystals showed no clear density for the
ISP, but the cluster could be located by iron anomalous scattering, at
low occupancy, near the Qo site. Our ﬁrst crystals, in three different
space groups, showed weak but interpretable density for the ISP, but
with the cluster in another position, near the cytochrome c1 heme
(distal, or c1 position). However when treated with stigmatellin
before crystallizing, the ISPwas foundwith the cluster near the Qo site
and in fact interacting with stigmatellin in the Qo site by a strong
H-bond [46] between the inhibitor and cluster-ligand His161 of the
ISP. Assuming ubiquinol binds in a similar fashion, this could provide a
pathway for one electron from ubiquinol to the ISP cluster. It had long
been realized that the ISP composed part of the binding site for
inhibitors like stigmatellin [53], and it had previously been proposed
that the cluster-ligand His residue(s) H-bond to substrate ubiquinol
[54], all of which ﬁt in nicely with this H-bond between H161 and the
inhibitor.
This H-bond between the inhibitor and the ISP provided a likely
explanation for the movement of the ISP, as an inhibitor capable of
forming the H-bond would stabilize the proximal position (in which theH-bond can be formed) relative to the distal [46]. An energetic analysis
based on the assumption that the ability of the Qo-site occupant to
H-bond the ISP was the main factor affecting the equilibrium between
different positions, was presented in 1999 [55]. We presented an even
more extreme H-bond-centric view of the bc1 universe in our 2003 FEBS
letters review [56].
This H-bond can also be seen in structures with bound nHDBT
(PDB ID codes2 1p84, 1sqv), the other inhibitor shown to promote the
b position. More recently it is seen with crocacin (3cwb) or ascochlorin
(3h1L); and can be inferred from low-resolution structures (LSH and
EAB, unpublished) with atovaquone and alkylhydroxynapthoquinones.
All of these structures show the ISP in the b position.
An alternate explanation for the effect of inhibitors on positionwas
proposed in 1998 by the Xia/Deisenhofer/Yu group [48] based on
results with tetragonal (I4122) beef bc1 crystals. They did not see large
changes in the position of the ISP, and emphasized rather the changes
in its occupancy. The effect of inhibitors on mobility resulted in
different states of the ISP, “ﬁxed” and “released”. The interpretation
was that a low occupancy implied most of the ISP was highly mobile
and visiting a continuum of positions with insufﬁcient occupancy in
any one other position to be visualized crystallographically. It is
important to understand the two different paradigms used to describe
mobility in the two different crystal forms, ﬁxed and released states vs
b and c1 positions, in order to synthesize the information provided by
the two different crystal forms.
1.4. Crystallographic occupancy as it applies to the ISP in the bc1 complex
For a homogeneous single chain protein, every residue of the chain is
present in the same amount: one per molecule. For a multi-chain
complex the same is true if it is assumed that the stoichiometry of the
chains is integral, i.e. no chain has been partially lost during puriﬁcation.
Thus every asymmetric unit of every unit cell will contain exactly one of
every residue (here we consider ncs-related chains, as in the case of a
dimer in the asymmetric unit, as different chains with different
residues). Now if every structure were identical, each atom would
occupy the same place in every asymmetric unit, in the amount of one
atom. This state is referred to as unit occupancy.
It is often observed that the electron density clearly indicates two or
more positions for some side chains. This indicates that two or more
conformations are present. [57, p. 224] Most crystallographic reﬁne-
ment software allow one to model alternate conformations and reﬁne
occupancy of each; usually with the sum of occupancies restrained to
unity. The occupancy is simply a scale factor by which the scattering of
each atom is multiplied in the process of calculating structure factors to
compare with the observe amplitudes, and the reﬁnement process
determines the occupancy which gives the best agreement with the
diffraction data. The physical interpretation is that that atom exists in
that position in only a fraction of the asymmetric units at a given time, or
for only a fraction of the time in any given asymmetric unit.
A less satisfactory situation arises when density is seen only in one
position, but the density is much less than expected if the atoms were
present at unit occupancy. If the atoms are disordered due to large
variation around central positions, this will be modeled by increasing
the temperature factor of these atoms, keeping the occupancy at 1.
However if the disorder is due to a number of quite different positions,
only one of which is present at high enough occupancy to detect, the
model clearly represents what is present in only a fraction of the unit
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a better ﬁt to the data. For single atoms the occupancy and
temperature factor are highly correlated, as both modify the height
of the density peak associated with the atom. For reﬁning occupancy
of single atoms, it is recommended to ﬁx the temperature factor at a
value typical of surrounding atoms before reﬁning occupancy.
However while the occupancy adjusts the total number of electrons
associated with an atom, and hence the integrated electron density
due to that atom, the temperature factor keeps the same number of
electrons and spreads them over a slightly larger area. Thus for a
cluster of atoms, temperature factor and occupancy can reliably be
reﬁned simultaneously (assuming the same occupancy for all atoms in
the cluster), as the integrated electron density determines the
occupancy. In the recent structures of chicken bc1 (3h1h–3h1L and
3L70–3L75), occupancy has been reﬁned for the extrinsic domain of
the ISP. Occupancy was restrained to the range 0.1 to 1, and reﬁned to
values between 0.79 (chain E of 3h1k) and 1.0 (in chain R of the
ascochlorin-containing structure and both chains of the two stigma-
tellin-containing structures). In those structures with the ISP in the c1
position, occupancy reﬁned to a lower value for the E chain than for
the R chain.
In the tetragonal crystals, height of the anomalous (Bijvoet
difference) peak due to the ISP cluster, relative to the peak for heme
bH, ranged from 0.244 to 1.2 [41,49,51], themaximumvalue of 1.2 being
with stigmatellin. Although the IS cluster has two irons compared to one
for hemebH, the two irons are obviously not in the sameplace so even at
low resolution their peak heights would not be additive. In addition the
greater mobility (in the sense of temperature factor, not alternate
conformations) of the ISP would tend to lower peak height for the
cluster. Thus it seems likely that the value of 1.2 with stigmatellin
represents 100%occupancy, as in the chicken complexwith stigmatellin,
and the values with no Qo inhibitor or with MOA inhibitors (0.244 to
0.517) represent less than 50% occupancy. This results in a pitfall for
correlating the conformation of cytochrome b with the position of the
ISP: The modeled position of the ISP represents the situation in a
minority of asymmetric units, because the majority have the ISP in the
“released” state, i.e. in a large number of different positions. However all
the distal positions presumably leave cytochrome b in the same, ISP-
undocked, state; and the model will tend to represent that majority
state, or a conformation between that of the undocked and docked state
if the two lie close together. Thus themodels for the ISP and cytochrome
b that are found in the PDB ﬁle may not actually coexist in the same
asymmetric unit in the crystal.
2. Materials and methods
Structures were obtained from the Protein Data Bank (http://www.
pdb.org), from which references to the associated publications can be
obtained. Details of structure solution for the recently solved structures,
and sources of the inhibitors used, are being published elsewhere.
Structures from the PDB were inspected using the molecular graphics
programO [58]. Figureswereprepared usingO,Molscript [59], Raster3D
[60], XV, PhotoshopR, Microsoft ExcelR, and ChemDrawR. Distances
between pairs of atoms in the structures were tabulated by using Unix
scripts to extract the atoms involved, run a Fortran program to calculate
the distances, and print them in tabular form.
Principal component analysis (PCA) of the structures—the entire
structures were superimposed based on the transmembrane helices of
cytochrome b to eliminate different positions in the unit cells of various
crystal forms as well as slight differences due to cell parameters in the
same crystal form. Cα coordinates in a segment of interest were
extracted from each structure, and a Fortran program was used to read
coordinates in .pdb format andwrite themout as vectors of 3n elements
(where n is the number of residues) in a format that can be read by a
homemade program we are using for spectral manipulation and
analysis. In this latter program the average structure was calculatedand subtracted from all, and the singular value decomposition was
carried out on the resulting differences. This programwas also used for
adding and subtracting a portion of each principle component to the
average structure, after which the format was converted back to .pdb
and displayed in O to illustrate the movement involved.
Note that the principal components thus derived do not correspond
to simple motions of the protein, but linear combinations of them.
Likewise the simple motions are linear combinations of the principal
components, so when one PC is plotted against another a simple linear
motion will show up as a straight line whose slope depends on the
relative contribution of those two PC's to the motion. Simple rotations
involve two principal components, but for small-scale movements
described here can be approximated as linear motions. No special
theoretical signiﬁcance is attached to the results other than that it
provides a way to classify different structures according to the most
strongly correlated motions separating them.
3. Results and discussion
3.1. Crystals of the bc1 complex with famoxadone or related compounds
display a new position for the ISP
As described in Section 1.3.3, the ability of some inhibitors to form
an H-bond with His161 of the ISP in the b positions seemed sufﬁcient
to account for the fact that the ISP was found in this position when
these inhibitors were bound. A normal H-bond has an energy on the
order of 4 kcal/mol, which is enough to make a change of nearly 1000-
fold in an equilibrium constant. However crystal structures of the bc1
complex inhibited by a new class of inhibitors, including famoxadone,
JG-144, and fenamidone, challenged the idea that the H-bond was
responsible for the b position and ﬁxed state. Fig. 3 shows the covalent
structures of fenamidone and famoxadone, as well the typical MOA
inhibitor azoxystrobin and a triazolone inhibitor from structure 3 L73.
Color highlighting is used to indicate parts that play the same role in
binding of the different inhibitors (discussed further below).
The ﬁrst structures with famoxadone (PDB ID 1L0L1) and JG144
(2fyu) were provided by the Xia lab at NIH [49,50]. They reported that
these inhibitors hold the ISP in the ﬁxed state (high occupancy) but do
not form a H-bond with the cluster-ligand His161. Yu, Xia, and
coworkers classify these new inhibitors, together with stigmatellin
and UHDBT, as Pf inhibitors: P-site inhibitors favoring the “ﬁxed” state
of the ISP. MOA and related inhibitors are called Pm for inducing the
“mobile” state [49,51].
Structures of the avian bc1 complex with famoxadone and another
related compound, fenamidone (Fig. 3A), from our lab conﬁrmed that
the ISP is held near the b position, moving to this position upon
soaking the inhibitors into crystals in which it occupied the c1
position. And there is no H-bond or any other direct contact between
the inhibitor and the ISP. This seemed especially surprising since the
pharmacophore of these inhibitors (highlighted in orange in Fig. 3A)
resembles that of the MOA inhibitors, which promote the c1 position.
However comparing the position of the ISP and its interaction with
cytochrome b (Figs. 4 and 5) shows that the position is not the same as
the b position induced by stigmatellin. Also intriguingly, although
there is no H-bond from the cluster-liganding His161 residue of the
ISP to the inhibitor, there is an H-bond formed between His161 and
Tyr279 of cytochrome b, which may be responsible for the position of
the ISP, as if Tyr279 were acting as a surrogate quinol to hold the ISP
in this position. In those structures with the ISP in the true b posi-
tion (e.g. stigmatellin, Fig. 4, left), this same Tyr279 is involved in
H-bonding a backbone carbonyl of the residue before H161 in the
cluster-binding loop 2 of the ISP. Interestingly, molecular dynamic
simulations suggested that Y279 would form an H-bond with H161 in
the process of moving from the b position to the c1 position [61,62],
long before any experimental structures showed this H-bond. This
interaction might serve a pre-docking function, holding the ISP near
Fig. 3. (A)Qo-site inhibitors famoxadone, fenamidone, the triazolone inhibitor JZZ, and the
typical MOA inhibitor azoxystrobin. Color highlights indicate portions of the molecules
having similar position and function in the binding pocket. (B) Crocacins bind like MOA's
but with a keto group (green) H-bonding His161of the ISP as with stigmatellin. The ISP is
held in the b position.
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the Qo site, and Tyr279 could pass on the His161 to the quinol OH, and
take up its new H-bond with the backbone.
In any case thenewH-bonding arrangement seenwith famoxadone-
like inhibitors positions the Fe2S2 cluster about 1.5 Å farther away from
the Qo site than in the b position. The altered H-bonding pattern
involves residues (C160, H161) in cluster-binding loop 2 of the ISP, so
this loop moves back while loop1 maintains essentially the same
interaction in crystals with famoxadone or stigmatellin. This causes the
extrinsic domain to pivot about a point in loop 1, rotating about 10° andcausing residues in sheet 1 on the other end of the extrinsic domain (e.g.
residues 76, 187, 193) to move as much as 5 Å between the b position
and famoxadone position.
To demonstrate that these two positions are signiﬁcantly different,
Fig. 5 classiﬁes the ISP position in available bovine and avian bc1
structures in comparison with that in the stigmatellin-containing
structure 1sqx. The structures were superimposed based on the rigid
transmembrane helices of the cytochrome b monomer. Then for each
structure the distance from the Fe2 atomof the ISP cluster in 1sqx to that
in the given structure, and the rotation angle through which the ISP
extrinsic domain of 1sqx had to turn in order to superimpose with that
of the given structure, were determined. When the structures are
arrayed in a scatter plot based on these two parameters (Fig. 5), they fall
into clear clusters.
Structures in the b position do not differ signiﬁcantly from 1sqx. This
includes all structures with stigmatellin or nHDBT (Pf inhibitors); from
chicken, beef tetragonal crystals. Although not shown, yeast and beef
orthorhombic crystals with stigmatellin, and chicken crystals with
ascochlorin (3h1L) or crocacin (3cwb) also fall in this cluster. It also
includes bovine structures from tetragonal crystals with no Qo-site
inhibitor.
On the other hand empty-site structures from chicken crystals
cluster together with structures with MOA-type (Pm) inhibitors from
chicken in the c1 position, with the ISP rotated about 57° from the b
position. Bovine structures from tetragonal crystals with Pm inhibitors
form another cluster, much closer to the b position but rotated about
20° from it. We call this the “released position” because this is where
the ISP is modeled in the released state structures, however it is
important to realize that in the released state the occupancy at the
released position is low, because most of the ISP is spread out over
many distal positions. It might be better to think of this as an alternate
ﬁxed position with lower afﬁnity and hence lower occupancy, and the
molecules in the released state are the ones that do not have the ISP in
this or any other ﬁxed position.
Most importantly for the current discussion, the three structures
with famoxadone-type inhibitors for which we consider the ISP
position to be reliable cluster into a group near but distinct from the b
position. The Fe2 atom is pushed back 1–2 Å farther than in the b
position, and the extrinsic domain is rotated about 10° as described
above. The structures of chicken bc1 with fenamidone (3L75) and
famoxadone (3L74) are essentially identical, and are the same as the
Xia group's recent high resolution structure with JG-144 from the
tetragonal crystal, 2fyu.
The original famoxadone structure 1l0l is different, with the ISP
essentially in the same orientation as with stigmatellin but with
the cluster pushed back to the famoxadone position. Additionally the
H-bond between Tyr279 and His161 of the ISP is not formed, however
the latter residue is in an impossible conformation with the Nε2 atom
closer to Fe2 than the Nδ1 atom and the Fe―N bond nearly
perpendicular to the plane of the imidazole. We suspect that the ISP
was initially mis-positioned outside the radius of convergence of the
reﬁnement protocol in this structure. Unfortunately the diffraction
data have not been deposited for this or any of the tetragonal crystals,
preventing an independent evaluation. In any case, our analysis of the
“famoxadone position” of the ISP is based on structures of the chicken
crystals with famoxadone or fenamidone, and 2fyu with JG-144 from
the tetragonal bovine crystals. The model of cytochrome b, on the
other hand, is essentially identical in all four structures.
3.2. Famoxadone-like inhibitors bind like MOA inhibitors but have a
second sidechain attached to the ester end of the pharmacophore
Asmentioned above the pharmacophore of famoxadone and related
inhibitors resembles, and binds like, that of the MOA inhibitors; which
promote the c1 state. The pharmacophore of typical MOA inhibitors like
azoxystrobin is the methyl ester of methoxyacrylate or something
Fig. 4. The ISP position in the presence of famoxadone (B) is not the same as the “b” position in the presence of stigmatellin (A). With stigmatellin, the tip of the ISP dips a little more
deeply into the crater allowing His161 to H-bond the inhibitor (white-bonded central ﬁgure indicated by arrows), and cytochrome b: Tyr279 to H-bond a backbone O of the ISP. Note
Famoxadone, like the MOA inhibitors such as azoxystrobin (C) forms an H-bond with N of the PEWY glutamate E272. The horizontal rule is at the same level in A and B relative to the
transmembrane helices of cytochrome b, showing the difference in position of the ISP at His161. Note that helix α-cd1 also moves slightly. The hydrophobic tails of the inhibitors,
stretching out behind in this view, have been truncated for clarity. AZX—azoxystrobin.
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azoxystrobin in Fig. 3A). In typical MOA-type inhibitors a hydrocarbon
side-chain is attached to the middle the pharmacophore, at C2 of the
acrylatemoiety. This attachmentpoint divides thepharmacophore itself
into an “ester” end and “ether” end (respectively right and left of orange
region in azoxystrobin of Fig. 3A). This side chain usually has a planar
group (aromatic ring or isoprenoid segment, purple dot labeled “1” in
Fig. 3A) separated from the pharmacophore by one bond.
Structure–activity relationship studies have shown that the car-
bonyl oxygen of the ester end (red in Fig. 3A) is the only functionalFig. 5. Positionsof the ISPextrinsicdomain indifferentcrystalsof thechickenorthorhombic
and bovine tetragonal forms with different inhibitors bound. After dimerizing the
monomeric structures using crystallographic symmetry and superposing based on
cytochrome b transmembrane helices, the position of the cluster and rotation of the
domain were compared to those in the presence of stigmatellin (1sqx) in terms of
rotational angle (x) and movement of Fe2 atom (y). This provides a 2-dimensional
classiﬁcation of the positions, in which they can be seen to cluster into groups. The group
labeled “c1 position” includes chicken crystalswith no inhibitor orMOA inhibitors, 3L71, 2,
3 and unpublished structures with myxothiazol and no inhibitor. The group labeled
“Released” includes tetragonal crystals with MOA inhibitors: 1sqb, p, q. “Famoxadone”
includes chicken and beef crystals with famoxadone, fenamidone, and JG-144 (3L74, 5;
2fyu anda second(unpublished) chicken crystalwith famoxadone). Finally the “b”position
includes chicken and beef crystals with stigmatellin, UHDBT as well as tetragonal beef
crystals with no Qo-site inhibitor or quinone: 1L0n, 1ntm, k, z, 1nu1, 1sqv, x; and 3h1i, j.group that is absolutely essential for activity [63]. Structures of beef and
chicken bc1 with MOA inhibitors bound show that the carbonyl O H-
bonds the backbone N of glutamate in the conserved PEWY sequence of
the ef-loop, Glu272 in the chicken sequence. The “ether” end of the
pharmacophore inserts in a pocket between the rings of Phe128 and
Tyr132 at the end of helix C. The planar group in the central side chain
ﬁts between Pro271 (of the conserved –PEWY– sequence of cyto-
chrome b) and the α-cd1 helix at residues Gly141, Val146, and Ile147.
As pointed out by Zheng [64] the triazolone and famoxadone-like
inhibitors (Fig. 3A) can be seen as MOA inhibitors with “tied-back”
MOA groups: the 5-atom heterocycle can be seen as being formed by
adding the atom labeled with * in the ﬁrst three compounds, to an
MOA-isosteric group at the position labeled * in azoxystrobin.
Structures with famoxadone, JG-144, or fenamidone bound have
conﬁrmed that they bind in such a fashion, with the keto group on
the heterocycle H-bonding PEWY E272 N as does the carbonyl oxygen
of azoxystrobin, and the other atoms indicated by the ellipses
superimposing with the pharmacophore of azoxystrobin. The pheny-
lamine substituent (purple) stacks against PEWY proline. Like acrylate,
the 5-membered ring is planar, whether aromatic or not. However the
atom corresponding to the ester methyl group is out-of-plane of the
ring in the famoxadone-like compounds, because the ring atom to
which it is attached has sp3 hybridization. Given this superposition, the
phenyl substituent of Fenamidone and the phenoxyphenyl group of
famoxadone (attached to the sp3 ring atom to which the methyl is
attached) can be seen as side chains attached to the ester end of the
pharmacophore. Because the structures show that this side chain
occupies a more proximal position in the binding pocket than the
centrally attached side chain, it is labeled “proximal side chain”. So in
looking for differences between the Famoxadone-like inhibitors and
MOA inhibitors that could account for their different effects on the ISP
position, three possibilities are apparent: the second side chain, the ring
closure of the pharmacophore, and the fact that the central side chain
has an extra atom (phenylamino N) between the pharmacophore and
the planar group.
3.3. A triazolone-based inhibitor serves as a “missing link” between
MOA- and famoxadone-like inhibitors
It turns out that a triazolone-based inhibitor developed by crop
protection scientists, of whichwewere fortunate to be given a sample,
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MOA vs. famoxadone inhibitors. This compound (Fig. 3A) is similar to
Famoxadone in that the pharmacophore is “tied back” in a closed ring,
but differs in that there is no second side chain attached to the “ester
end” of the pharmacophore. The planar group in the central side chain
is connected by a single bond as in MOA inhibitors, but it is a large
napthalene ring. We have determined the structure of the chicken bc1
complex with this compound bound (PDB ID 3L73), and veriﬁed
that the triazolone ring closely overlays the methoxyacrylate atoms
of MOA inhibitors such as azoxystrobin, with the carbonyl oxygen
H-bonding PEWY Glu272 N. The 5-membered rings of fenamidone
and famoxadone bind essentially the same way but with the plane of
the ring at a slight angle due to the fact that the out-of-plane methyl
group mentioned above locates in the same pocket as the planar
methyl in the triazolone or MOA structures. However unlike the
structures with famoxadone, the ISP is in the “c1” state in crystals with
the triazolone bound. Thus the cyclized pharmacophore alone does
not result in capture of the ISP at Qo, and the second side chain
becomes a good candidate for this role, as discussed in Section 3.5.3.
3.4. An inhibitor that combines features of MOA-type compounds and
Stigmatellin and holds the ISP in the “b” position
Crocacins A and D are potent inhibitors of the bc1 complex isolated
from the myxobacterium Chondromyces crocatus [65]. We recently
had the opportunity to determine the structure (PDB ID 3cwb) of the
chicken bc1 complex with an analog of Crocacin D bound [66], and
found that the ISP was in the b position, well within the cluster of
stigmatellin structures in Fig. 5. The mode of binding had features of
stigmatellin but also of MOA inhibitors. Speciﬁcally the methylglycine
moiety binds in the position of the pharmacophore of MOA inhibitors,
with the ester carbonyl oxygen H-bonded to E272 N. The N of the
methyglycine moiety does not superpose with the pharmacophore
but rather with the ﬁrst atom of the central side chain so that, as
indicated in Fig. 3B, the ether end of the pharmacophore is completely
absent. An H-bond between the carbonyl oxygen and NH of the two
amide linkages bends the molecule in a hairpin. The ﬁrst amide
linkage provides the planar group (indicated by purple) inserting
between the PEWY proline and cd1 helix. The carbonyl O of the second
amide linkage, highlighted green, is in the same position as the
carbonyl of stigmatellin, and like it H-bonds to His161 of the ISP. This
H-bondmay explain why the ISP is found in the b position, despite the
MOA-like features of the pharmacophore.
The crocacin analog is thus another example of the correlation of
the true b position with an H-bond from inhibitor to H161. In
unpublished results from our lab, low-resolution structures with
atovaquone and two alkyl hydroxynapthoquinones have the ISP in the
b position and show electron density connection between the blob
assigned to the inhibitor and His161. The dual-site inhibitor
ascochlorin also holds the ISP in the b position and shows direct
interaction between the inhibitor and the ISP His161. And we are
workingwith another compound that bindsmuch like Crocacinwith a
1-sided pharmacophore H-bonding E272 N. This compound lacks the
carbonyl O of crocacin that binds the ISP, and it leaves the ISP in the c1
position. Thus with the exception of the famoxadone-like inhibitors,
there is a strong correlation between the ﬁxed state and the presence
of an H-bond between the inhibitor and His161 of the ISP.
3.5. Conformational changes in the ISP-docking surface of cytochrome b
Although the most dramatic differences seen in different crystals
of the bc1 complex involve movement of the ISP, changes in
cytochrome b also occur [for example, 49,52,62]. Comparing a
stigmatellin-bound structure to one with no inhibitor [52], movement
of the cd1 helix was interpreted as responding to contact pressure
from the docking ISP, andmovement of the ef-helix as widening of thegap between cd1 and ef-helix to accommodate the inhibitor. Crofts et
al. compared structures with stigmatellin and myxothiazol and
described a rotation of the ef loop around the conserved –PEWY–
sequence, the “PEWY seesaw”. Esser et al. [67] interpreted movement
of the PEWY proline which did not correlate with the type of inhibitor
(Pf vs Pm) as widening the binding cleft to accommodate inhibitors.
Movement of the cd1 helix, which did correlate with the type of
inhibitor, was considered potentially part of the signaling pathway by
which the inhibitor affects the position of the ISP. However this
assignment is uncertain, as any structure which has bound an
inhibitor that favors the docked state of the ISP will have the ISP
docked, and therefore it is impossible to say whether a structural
change was caused by pressure from the docking ISP (induced ﬁt) or
was caused by inhibitor binding and results in docking the ISP. This is
not an intrinsically unanswerable question. For example the effects
of inhibitor binding could be measured under conditions where the
ISP is removed from the picture, either completely or by preventing its
approach to the docked position. In that case if the same structural
changes are seen upon inhibitor binding, it would indicate that
inhibitor binding is the cause, and perhaps ISP docking is the result, of
the conformational change.
It might seem that an answer to this question could be provided by
the fact that the uninhibited complex has the ISP in the ﬁxed b
position in the tetragonal crystals, but in the distal position in the
chicken crystals. Thus if a change in the conformation of cytochrome b
results from the position of the ISP independently of the nature of the
inhibitor bound, then native crystals of the tetragonal form should
have cytochrome b in the same conformation as with stigmatellin,
because the ISP is in essentially the same position as with stigmatellin
(Fig. 5). On the other hand in the native chicken crystals that feature
should be the same as in the presence of MOA inhibitors, because the
ISP is in the same c1 position in both. In fact this reasoning is not valid
for the tetragonal crystals because of the pitfall mentioned earlier
having to do with the low occupancy of the ISP in the empty-site
tetragonal crystals: the position of the ISP represents the state in a
minority of asymmetric units which have this position, judging by
height of the cluster anomalous peak, while the conformation of
cytochrome b is likely to reﬂect the state in the majority of
asymmetric units in which the ISP is in some distal position.
As for Pm inhibitors, in principlewe can look at their effect with the
chicken bc1 crystals, since the ISP is in the same c1 position with no
inhibitor and with Pm inhibitors. We have recently succeeded in
crystallizing the ISP-depleted bc1 complex of von Jagow and co-
workers [68–71], which has an intact Qo site as far as binding MOA-
type inhibitors, and this may allow us to study conformational
changes in the absence of the ISP movement. However the very low
afﬁnity of this complex for Pf inhibitors (ref. [71], and unpublished
observations of LSH and EAB) may frustrate attempts to get deﬁnitive
measurement of changes induced by Pf inhibitors.
3.5.1. Movement of the cd1 helix
If we measure the distance from residue 147 in the cd1 helix to
residue 126, which is in approximately the direction the helix moves
on binding stigmatellin, it is around 11.5 Å with MOA inhibitors
(either chicken or tetragonal beef) and 9.6 Åwith stigmatellin (Fig. 6).
Chicken structures with no inhibitor (“empty site” in Fig. 6) are not
signiﬁcantly different (11.5 Å) from those with MOA inhibitors. Thus
there is no evidence for movement of the cd1 helix along this direction
on binding MOA inhibitors, when the ISP stays in the c1 position.
In the empty site structures from tetragonal crystals, this distance is
only slightly shorter (~11.1 Å) than in the chicken structures in c1
position. But these structures have the ISP in the b position, the same as
with stigmatellin butwith lower occupancy judged from the anomalous
signal. This might seem to imply that movement of the ISP to the bc1
position is not sufﬁcient to give the movement of the cd1 helix, which
would then seem to be a result of inhibitor binding. But as explained
Fig. 6. Position of the cd1 helix in various structures as measured by the distance (Ca–Ca) of residue 147 from 126. The structures are designated by their PDB ID codes with the
exception of ant08a and fmx802 which are 8unpublished chicken bc1 structures containing antimycin and famoxadone, respectively.
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high occupancy, with the ISP distributed over a range of distal positions
that do not impinge on the cd1 helix, rather than the low-occupancy
state in which the ISP is modeled. The slight difference from the MOA
position may result from the reﬁnement process; in which simulated
non-bonded interactionswith the ISP in thebpositionwould exert some
pressure on cytochromeb.What lowoccupancy there is in thebposition
may result from endogenous quinone binding like stigmatellin but at
too low occupancy to visualize in the electron density.
In order to classify structural changes without arbitrary choice of a
pair of residues to monitor, we subtract the average from a group of
structures and perform principal component analysis on the differ-
ences as described in Section 2. Each structure can then be classiﬁed
by the amount of each principal-component motion that needs to be
added to the average structure to make that structure. The structures
can then be compared by plotting each structure as a point on an X–Y
graph where X is the amount of the ﬁrst, and Y the amount of the
second, principal component. The type of movement resulting from
each principal component can be displayed by adding and subtracting
the principal component to/from the average structure and displaying
the results using a molecular graphics program.
To look at the cd1 and cd2 helices, we selected residues 129 to 177
(128 to 176 in the bovine numbering). PCA was performed on 32
bovine and chicken structures. Yeast structures were excluded due to
a major difference around residue 169 (probably due to replacement
of residue Arg92 in the ISP with Gln in yeast), which is not relevant to
the question at hand. Fig. 7 illustrates the ﬁrst three principal
components (7a) and plots each of the structures by its component
along principal components 1 and 2 (7b). From the plot it can be seen
that the ﬁrst principal component correlates with the type of inhibitor
or position of the ISP, while the second principal component seems to
report mainly species- or crystal-form-dependent differences. Look-
ing at the motions involved, the ﬁrst principal component corre-
sponds mainly to up-and-down ﬂexing of the cd1–cd2 hairpin, with
the largest changes just before the tip. Thus it is not surprising that it
correlates well with the distance from 147 to 127 plotted in Fig. 6.
Again we are left with the question whether the motion results from
docking of the ISP induced in an unknown fashion by the inhibitor, oris induced directly by the inhibitor and results in the position of the
ISP. Fig. 8 shows the motion of the ﬁrst principal component in the
context of the structure, together with the iron–sulfur protein in the b
position, stigmatellin, and Pro271; and it is easy to imagine this
motion of the ef1 helix results from pressure from the iron–sulfur
protein where cluster-binding loop 1 contacts helix cd1.
Note that in the plot of Fig. 7B, the tetragonal bovine crystals with
empty Qo site, such as 1ntm, 1L0n, and 1ntk (which have the ISP
modeled in the b position) nearly coincide on the ﬁrst axis with the
chicken crystals with empty site or MOA inhibitors (which have the
ISP in the c1 position). Again the explanation could be that in these
structures cytochrome b represents mainly the majority situation,
with the ISP away from the docking site and cd1 helix.
3.5.2. Movement of –PEWY– and the ef-loop
As suggested [52,67], one component of movement of the –PEWY–
region has to do with widening the inhibitor binding pocket,
speciﬁcally the slot between the PEWY Proline and the cd1 helix
where the portion of inhibitors labeledwith purple in Fig. 3 binds. This
motion correlates with presence or absence of inhibitor, but not with
the type of inhibitor with respect to effect on ISP position (Pf/Pm).
However Crofts et al. [62] pointed out another motion in this region
when comparing structures with stigmatellin andmyxothiazol, which
does correlate with the type of inhibitor. This “PEWY seesaw”motion
involves rotation of the stretch from 267 to 272, pivoting near 270–
271 (Fig. 9), with the largest motion at 268. The region from 269 to
272 also slides downward (in the orientation of Fig. 10) some, as can
be seen by comparing the positions of side-chains in this region in
Fig. 9. Crofts et al. also noticed movement of the side-chain of Tyr279,
the “trapdoor” tyrosine, which H-bonds to the carbonyl O of I169 in
those structures that have the ISP in the c1 position, and to Cys160 of
the ISP in the stigmatellin-containing structures. Note this is the same
tyrosine which we now see H-bonding His161 in the famoxadone-
containing structures (Fig. 4). The alternate interactions of this
residue in the presence of stigmatellin andMOA inhibitors (Kresoxym
in this case) are also illustrated in Fig. 9.
The H-bond from Tyr279 to Ile269 and the “PEWY seesaw” are
likely to be related, because the inward and downward movement of
Fig. 7. Principal component analysis of the movement of the cd1–cd2 helix hairpin. The sequence corresponding to 129–227 of chicken cytochrome bwas taken from 32 structures.
As described in Methods (Section 2), the average was subtracted from all and the resulting changes were subjected to singular value decomposition to determine principal
components, which are illustrated in A. In each case the black trace is the average structure, the red has a fraction of the principle component subtracted, and the blue has the same
fraction added. Arrows indicate the direction of change. The position of stigmatellin is indicated. In B each structure is plotted as a point located by its component along the ﬁrst two
principal components, i.e. how much of each principal component would be used to reconstruct that structure. Ovals are drawn around what are perceived to be clusters.
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formation of a strong H-bond (or, perhaps more likely, formation of
this H-bond pulls the ef-loop inwards and down resulting in the
seesaw movement). The downward movement of the proline may
also be related, as the proline ring is in van-der-walls contact with the
tyrosine ring in all these structures, so tyrosine H-bonding I269 in theFig. 8. The cd1–cd2 motion represented by principal component 1, placed in context of
the structure. Compare Fig. 5 of [52] and Fig. 2a of [49]. Is the motion caused by docking
of the ISP, or does it control docking?MOA position would make a closer than van-der-Waals (2.55 Å) C―C
contact with proline in the stigmatellin position (See Fig. 9). Thus in
addition to bringing I269 in closer to Y279, the downward movement
of Pro271 allows Y279 to swing down for a better H-bond to I269
(Fig. 9).
To analyze backbone movement in the ef-loop region, we selected
residues 241–291 (chicken numbering) and performed principal
component analysis (Fig. 10). The plot in Fig. 10B shows that the ﬁrst
principal component is sensitive to the type of inhibitor, with the Pf
inhibitors givingmore negative values; but also to the species or crystal
form: the chicken structures are more positive than the bovine, except
that for the structures in the b position (most with stigmatellin),
chicken, yeast, and two beef crystal forms occupy the same region alongFig. 9. PEWY seesaw and trapdoor tyrosine. Comparing stigmatellin (3h1j, brown) and
kresoxym (3L72, green). The protein backbones are shown as thick worms, side chains
as stick ﬁgures, and inhibitors stigmatellin and kresoxym as thin stick ﬁgures.
Fig. 10. Principal component analysis of the movement of the ef-loop. Top: ﬁrst three principal components of motion of the ef-loop (residues 241–291, between helices E and
F) from 34 structures of vertebrate bc1 complex, represented as in Fig. 8. Below: each of the structures is plotted in the 2-D space spanned by the ﬁrst two principal components, to
show segregation of inhibitor classes.
3 Reference to different rotamers of side chains are made with respect to the
numbering convention used in the O library, which in turn is derived from the rotamer
library of Ponder and Richards [76].
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movement mainly around 268 and 262. The former is the PEWY
seesaw, and explains the correlation with type of inhibitor. The latter is
at the tip of the ef loop, and probably represents the different interaction
of the ISP with the tip of the ef loop when in the c1 position. Since the
tetragonal crystals do not have signiﬁcant occupancy in the c1 position,
this could explain the clear separation of chicken and bovine structures
with MOA inhibitors or empty Qo site, in which the chicken structures
have the ISP in the c1 position and the tetragonal bovine crystal
structures do not.
The movement of the second principal component is mainly around
271 and (although not obvious from this orientation) represents
narrowing of the inhibitor pocket. In the plot the structures with
emptyQo site havemore positive values of PC#2. Interestingly the yeast
structures with stigmatellin are well separated in this dimension form
the vertebrate ones with the same inhibitor.
3.5.3. A different path for the hydrophobic “tail”, and alternative
H-binding possibilities for Tyr279
Tyr279 is especially interesting with respect to explaining the
famoxadone position. Famoxadone holds the ISP at high occupancy in a
position near cytochrome b, but there is noH-bond from the inhibitor to
the ISP H161 as seen with stigmatellin, UHDBT, atovaquone, hydro-
xynapthoquinone, and NNQNO. However there is an H-bond from
Tyr279 to H161. Could it be responsible for stabilizing the ISP in the
famoxadone position?But Tyr279 is present irrespective of the inhibitor
bound, so why would this H-bond be formed speciﬁcally in the pres-
ence of famoxadone (unless it is a result rather than a cause of the
famoxadone position)?
One possibility involves a conformational change of F275 that is
seen speciﬁcally in the structures with famoxadone-type inhibitors.
As reported for the beef tetragonal crystals [50] and as illustrated in
Fig. 11, Phe275 is found in a different conformation in the presence of
famoxadone-type inhibitors. With no inhibitor or with any other Qoinhibitor tested so far, F275 is close to rotamer3 1 at least as far as
rotation about Chi1 goes. However the proximal tail of famoxadone
and related inhibitors would clash with this position (Fig. 11A). In the
famoxadone structure (Fig. 11B), F275 has swung to a position near
rotamer 2 allowing the proximal tail of the inhibitor to pass.
Interestingly, this new rotamer would clash with the distal tails of
kresoxym and other Qo-site inhibitors, so the conformation of F275 is
absolutely controlled by the type of inhibitor. It is conceivable that the
conformation change also involves a slight movement of the ef helix,
which has both F275 and Y279, and reorients the latter residue to
affect the relative strength of its H-bonds to I269 or H161. However no
signiﬁcant movement of the ef helix is seen in the current structures.
A second explanation involves competition between residue I269
in cytochrome b and residue C160 in the ISP for H-bonding with Y279.
The H-bonds to I269 and C160 involve carbonyl oxygens, which can
only be H-bond acceptors, and since Y279 has only one proton these
H-bonds are mutually exclusive. His161 is partially protonated at
neutral pH, and fully protonated if in the reduced form, so it could be
an H-bond donor to Y279. However the strength of H-bonds is
sensitive to geometry, and it is plausible that the conformation of
Y279 which makes a strong H-bond with I269 would not make a
strong H-bond with H161, making these also mutually exclusive. If Pf
inhibitors somehow destabilize the H-bond to I269, and/or if Pm
inhibitors stabilize it, the availability of Y279 to capture the ISP could
be modulated by the inhibitor.
Evidence for modulation of the stability of this H-bond by Pm
inhibitors comes from comparing the H-bond length in the presence
of MOA inhibitors with that in empty-site structures. In all the chicken
structures with MOA inhibitors (3L70, 1, 2, 3), the H-bond from Y279
to I269 is ≤3 Å (2.46, 2.42, 2.67, 3.02, 3.01). In the empty-site
Fig. 11. Stereo ﬁgure comparing famoxadone and kresoxym binding positions in the Qo site. A. Structure 3L72 with kresoxym (thin yellow stick ﬁgure). Famoxadone (magenta) is
placed from the 3L74 structure after superimposing based on the transmembrane helices of cytochrome b. Note aromat stacking between the second ring of kresoxym and F275, the
clash between famoxadone and F275, and the close approach of famoxadone to the Y279-I269 H-bond. B. Structure 3L74 with famoxadone (magenta stick ﬁgure). Note
conformational change in F275, breakage of the Y279-I269 H-bond, and capture of the ISP. (This ﬁgure is also available as a stereo ﬁgure for cross-eyed viewing and as a rocking gif in
the supplemental materials on the publisher's website).
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(unpublished), this distance is in the range 3.13–3.57. It appears that
contact between Y279 and the PEWY proline P271 prevents a shorter
H-bond in the empty-site structures. Speciﬁcally, Pro271 in the
position it has in the empty site structures would make a closer-than
van-der-Waals contact with Y279 in its position from 3L70, 1, 2. It may
be that the widening of the inhibitor pocket when the inhibitor is
present moves Pro271 to the side allowing Y279 to swing down and
make a closer bond with I269.
As for Pf inhibitors, which also widen the inhibitor pocket, and
speciﬁcally famoxadone, the case we are trying to explain, the PEWY
seesaw movement described earlier would prevent a short H-bond
between Y279 and I269, both by moving I269 farther away in the Pf
state, and by moving P271 upwards displacing Y279. However as
mentioned before the direction of causation is unclear here: It is quite
plausible that the seesaw motion results from making and breaking
the H-bond, and not the other way around.
Another possibility is that the inhibitor itself directly destabilizes
the H-bond to I269. As can be seen in Fig. 11A, the phenylamino ring of
famoxadone reaches up closer to Y279 than does the bridging ring of
azoxystrobin. This suggests a “booby trap”mechanism for ISP capture
by famoxadone: The inhibitor bumps its head on the H-bonded pair,
destabilizing the H-bond and releasing Y279 to ﬂy up and capture the
ISP. However a careful examination of the distances involved does notsupport this, at least for famoxadone and relatives: The closest
approach of famoxadone to the position of Y279 in the kresoxym
structure is 3.55 Å, a comfortable van-der-Waals contact. Stigmatellin
makes more of a clash, at 2.37 Å, but even there the movement of
Y297 away from the inhibitor doesn't stretch the H-bond much: in
both cases the rupture of the H-bond is duemore tomovement of I269
away from Y279 by the PEWY seesaw.3.6. Mutagenesis and epr spectroscopy probe the function of Y279
Y279 in cytochrome b is highly conserved among proteobacteria
andmitochondria (It is replaced by phenylalanine in cytochrome b6f).
Ile169 is also highly conserved, but of course this is not required for
the H-bonding function of its carbonyl group. F275 is replaced with
leucine in fungi. Mutants at Y279 and F/L275 have become available
through selection for inhibitor resistance, either intentional [72] or
through the use of inhibitors to control pathogens [13,15], and
through site-directed mutagenesis [62,73–75]. The mutation Y279F
apparently has little effect on the turnover of the enzyme [62] (also
Lee and Daldal, personal communication; and H. DeBari, unpublished
results) and is not highly resistant to famoxadone. Thus the capture of
the ISP by Y279 is not essential for turnover or for famoxadone
binding and inhibition.
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of electron transfer from the ISP to cytochrome c1. In the absence of
inhibitors in Rhodobacter this rate was 80,000 s−1, reduced to 4800 s−1
by famoxadone. Because the electron transfer from the c1 position
should be N106 s−1, this was considered to measure the rate of release
of the ISP from the ﬁxed position, which should be reduced in the
presence of famoxadone based on the crystallographic observation that
this inhibitor results in ﬁxation of the ISP. The uninhibited rate was
reduced to 1200 s−1 in a mutant with the residue corresponding to
Y279 replace by cysteine. Addition of famoxadone to themutant further
reduced the rate only to 7600, actually faster than the inhibited wild
type. This could be interpreted to say the ISP is ﬁxed less tightly by
famoxadone because the H-bond to Y279 cannot be formed, but any
conclusionwould be speculative aswe don't understand the decrease in
uninhibited rate. Repeating the experiment with the mutant Y279F,
which presumably doesn't greatly affect the uninhibited rate but does
abolish the H-bond, would be informative.
3.7. Complimentary relation between binding afﬁnity and ISP position
If binding an inhibitor at the Qo site promotes docking of the ISP in
the b position, then completing the thermodynamic cycle shows that
docking of the ISPmust increase the afﬁnity for the inhibitor. Thus if the
ISP canbeprevented fromdocking in thebposition, by cross-linking it in
the c1 position or by removing it altogether, the afﬁnity for the inhibitor
should be lowered. In other words, docking of the ISP and binding the
inhibitor will be mutually stabilizing. Brandt and co-workers [71] have
shown that the afﬁnity for stigmatellin is drastically reduced in the ISP-
depleted complex. Recentwork inour labhas shown that this is truealso
for famoxadone (LSH and EAB, unpublished results). While the ISP-
depleted complex is also somewhat depleted of lipids, the simplest
explanation is that high-afﬁnity binding of famoxadone requires
interaction of the ISP in the famoxadone position.
In the case of stigmatellin, the mutual stabilization can readily be
explained as being a result of the H-bond between the bound
inhibitor and the ISP in the b position. Not only does the H-bond
hold the ISP in this position, but also the ISP in this position provides
an important part of the binding site for the inhibitor. One can
imagine the ISP and the inhibitor transiently visiting their sites until
they arrive at the same time, the bond forms, and they are locked in
for an extended time. However with famoxadone there is no direct
interaction between the inhibitor and the ISP. The ISP is presumably
captured by some conformational change induced by the inhibitor, be
it a change in surface complimentarity such as downward movement
of the cd1 helix, or a change in the availability of H-bonding partners.
This conformational change requires energy, which detracts from the
negative binding energy of the inhibitor, i.e. reduces its afﬁnity.
However the fact that the conformational change stabilizes the
famoxadone position of the ISP implies that the famoxadone position
of the ISP stabilizes the conformational change, thus increasing the
afﬁnity for the inhibitor.
Involvement of speciﬁc residues such as Y279 and F275 in the
mutual stabilization can be tested bymutating these residues: Y279 to
Phe to eliminate the H-bond, and F275 to Ala to remove the steric
interaction which produces the conformational change of this residue
in the presence of famoxadone. Ideally the effect will be tested by
crystallizing the mutant complexes with famoxadone bound, and
determining the state of the ISP. While working toward this goal, the
importance of these residues can be tentatively probed by looking at
the afﬁnity of the mutant complexes for famoxadone. If the
mechanism by which famoxadone induces the famoxadone position
of the ISP involves the H-bond from Y279, then the same interaction
must be involved in the effect of ISP on the afﬁnity for the inhibitor.
And just as the ISP-depleted bc1 has low afﬁnity for famoxadone, the
mutant complex should as well. However effects of famoxadone on
the ISP epr spectrum in mutants of the residue in Rb capsulatusequivalent to Y279 suggest binding occurs at the normal concentra-
tions (personal communication, Daldal and Lee). Preliminary results
with the Y279F mutant in yeast also do not show a large decrease of
afﬁnity (personal communication, H. DeBari). Such results do not
support the importance of Y279 in the mechanism by which the
famoxadone-like inhibitors result in capture of the ISP.
4. Conclusions
With the exception of the famoxadone-like inhibitors, the effect of
inhibitors on ISP position could be accounted for by the ability of the
inhibitor to form an H-bond with His161 of the ISP. However the
existence of this class that cannot be explained so simply points to a
more subtle, probably conformational, coupling between the occupant
of the Qo site and the position of the ISP. Such coupling clearly could
be involved in the enforcement of the bifurcated reaction. We have
not been able to determine the mechanism of this coupling so far,
but have pointed out several possible types of mechanisms for
consideration.
Further investigations that could help solve this riddle can be
imagined. Studies of structural changes induced by inhibitors in the ISP-
depleted protein, or in crystals in which the ISP is held in the c1 position
by a disulﬁde cross-link or crystal contacts, can help resolve whether
these changes are causedby inhibitor bindingandmaypromotedocking
of the ISP, or are simply a result of docking of the ISP. Site directed
mutagenesis of residues suspected of being involved could determine
their importance, ﬁrst for energy coupling but eventually on the
crystallographically determined position of the ISP. EPR spectroscopy
can be a sensitive probe of the position and environment of the ISP
cluster, and how it is affected by inhibitors in wild-type and mutant
strains. Finally, if a way is found to disrupt the coupling between ISP
position and inhibitor bound, testing the effect of this on energy
coupling and on inhibition by antimycinwill help decidewhether or not
this has anything to do with the mechanism of energy coupling.
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